Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2319]

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC

Dr Saby George - Roswell Park Comprehensive Cancer Center, New York, USA

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC ( Dr Saby George - Roswell Park Comprehensive Cancer Center, New York, USA )

Cabozantinib and atezolizumab show more efficacy compared to second NHT in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple...

Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy ( Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium )

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

Preoperative endocrine therapy in premenopausal women leads to sparing...

Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )

Significant clinical benefits observed with revumenib monotherapy in relapsed...

Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA

$Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia ( Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA )$

Ide-cell enhances health-related quality of life for refractory multiple myeloma

Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium

$Ide-cell enhances health-related quality of life for refractory multiple myeloma ( Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium )$

Zanidatamab, palbociclib and fulvestrant show positive results in treating...

Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO)...

Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC ( Dr Santiago Escrivá-de-Romani - Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2...

Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer ( Dr Hongnan Mo - National Cancer Center/Cancer Hospital, Beijing, China )

BrECADD combined with PET2-guided treatment sets a new benchmark for the...

Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany

BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL ( Dr Peter Borchmann - University Hospital Cologne, Cologne, Germany )

More from ecancer